# US 2025/0152544 A1 · Sleep-improving compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152544 A1
- Document ID: US20250152544A1
- Status: Published application
- Kind: A1
- Application number: 19/022,909
- Filed: 2025-01-15
- Published: 2025-05-15
- Earliest claimed: 2023-05-15
- Assignees: Bonafide Health, LLC
- Applicants: Bonafide Health, LLC
- Inventors: James R. Komorowski; Devon Bernsley
- Web page: https://patentgrep.com/patent/US20250152544A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions comprising two or more sleep-inducing agonists and/or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.

## Claims

### Claim 1

A method of improving poor sleep quality or maintaining healthy sleep quality in a subject, the method comprising:
identifying the subject who is experiencing or will experience poor sleep quality, and
administering a composition to the subject, wherein the composition comprising two or more sleep-inducing agonists, wherein a first sleep-inducing agonist is L-theanine and a second sleep-inducing agonist is a magnesium salt, wherein L-theanine and the magnesium salt are present in a synergistic ratio of about 2:1 by weight.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises a sleep-inducing antagonist, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

### Claim 3 (depends on 1)

The method of claim 1, wherein the magnesium salt is magnesium glycinate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises a third sleep-inducing agonist, wherein the third sleep-inducing agonist is gamma-aminobutyric acid (GABA).

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

### Claim 6 (depends on 4)

The method of claim 4, wherein the composition further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

### Claim 7 (depends on 6)

The method of claim 6, wherein the gallic acid ester is propyl gallate.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

### Claim 10 (depends on 9)

The method of claim 9, wherein the gallic acid ester is propyl gallate.

### Claim 11 (depends on 9)

The method of claim 9, wherein the composition further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

### Claim 12 (depends on 2)

The method of claim 2, wherein the composition further comprises propyl gallate.

### Claim 13 (depends on 4)

The method of claim 4, wherein the amount of the magnesium salt, the amount of L-theanine, and the amount of GABA are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3 of the magnesium salt to L-theanine to GABA by weight, respectively.

### Claim 14 (depends on 5)

The method of claim 5, wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:1 of the magnesium salt to L-theanine to GABA to phosphatidylserine by weight, respectively.

### Claim 15 (depends on 7)

The method of claim 7, wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.12 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate by weight, respectively.

### Claim 16 (depends on 8)

The method of claim 8, wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.125:1 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate to phosphatidylserine, respectively.

### Claim 17 (depends on 10)

The method of claim 10, wherein the amount of the magnesium salt, the amount of L-theanine, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate by weight, respectively.

### Claim 18 (depends on 11)

The method of claim 11, wherein the amount of the magnesium salt, the amount of L-theanine, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125:1 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate to phosphatidyl serine by weight, respectively.

### Claim 19 (depends on 1)

The method of claim 1, wherein the poor sleep quality is caused by caffeine.

### Claim 20 (depends on 19)

The method of claim 19, wherein the composition is administered to the subject prior to, simultaneously with, or after consuming caffeine-containing drinks, foods, and/or supplements.

### Claim 21 (depends on 20)

The method of claim 20, wherein the supplements are caffeine-containing pre-workout supplements.

### Claim 22 (depends on 1)

The method of claim 1, wherein the poor sleep quality is caused by menopause.

### Claim 23 (depends on 1)

The method of claim 1, wherein the composition is formulated as a single dosage form.

### Claim 24 (depends on 1)

The method of claim 1, wherein the composition is administered orally, buccally, or sublingually.

### Claim 25 (depends on 1)

The method of claim 1, wherein the composition is administered to the subject orally between 15 minutes and 2 hours before bed.
